Dataset from A 48 Week, Phase II, Open-Label Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and GW433908/Ritonavir BID When Administered to HIV-1 Infected, Antiretroviral Naive and Experienced, Pediatric Subjects 2-18 Years Old
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009182
下载链接
链接失效反馈官方服务：
资源简介：
This is a 48-week study to collect additional information on the safety, tolerability,
pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy)
including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
创建时间：
2024-11-27
